ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 670,57
1,24%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MaxCyte Inc (MXCT)

  7. MaxCyte Inc (MXCT) Actualités

MXCT MaxCyte Inc

3,77
-0,06 (-1,57%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
MaxCyte Inc MXCT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,06 -1,57% 3,77 00:30:10
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,95 3,74 3,95 3,77 3,83
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
10/4/202414:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
02/4/202414:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
12/3/202421:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
05/3/202422:15EDGAR2Form 8-K - Current report
04/3/202423:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202422:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
26/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202414:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
01/2/202422:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202414:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
26/1/202422:45EDGAR2Form 8-K - Current report
26/1/202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202414:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
08/1/202422:15EDGAR2Form 8-K - Current report
08/1/202422:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
04/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
02/1/202408:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
28/12/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:30EDGAR2Form 8-K - Current report
11/12/202322:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
06/12/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202323:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:32EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/11/202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202314:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
08/11/202323:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:12EDGAR2Form 8-K - Current report
08/11/202322:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
06/11/202322:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
04/10/202322:14EDGAR2Form 8-K - Current report
04/10/202322:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..
06/9/202314:05GLOBEMaxCyte Appoints Ali Soleymannezhad as Executive Vice..
05/9/202314:05GLOBEMaxCyte to Participate in Baird Global Healthcare Conference
30/8/202323:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:16EDGAR2Form 8-K - Current report
09/8/202322:05GLOBEMaxCyte Reports Second Quarter and Half-Year 2023 Financial..
01/8/202314:05GLOBEMaxCyte Signs Strategic Platform License with Prime Medicine..
28/7/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202314:05GLOBEMaxCyte to Report Second Quarter 2023 Financial Results on..
13/7/202300:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202322:51EDGAR2Form 144 - Report of proposed sale of securities
10/7/202314:05GLOBEMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform..
06/7/202314:05GLOBEMaxCyte Signs Strategic Platform License with Lyell..

Dernières Valeurs Consultées

NASDAQ
MXCT
MaxCyte
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés